Objective: To evaluate the efficacy and tolerability of opicapone in patients in Parkinson’s disease (PD) patients with early/simple motor fluctuations (E/S-MF) in the Spanish clinical practice setting.
Background: Opicapone is indicated as adjunctive treatment to levodopa /dopa-decarboxylase inhibitor therapy in adults with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations
Method: We revised all Spanish studies reporting data on the use of opicapone in the real clinical practice and included those studies reporting data for patients with E/S-MF
Results: Among the 27 studies conducted in the real practice setting, we found 6 studies reporting data with opicapone in patients with PD and E/S-MF. All 6 studies were retrospective. Among 34 patients with available data (Labandeira et al 2019; Gómez Mayordomo 2020), 21 (61.8%) reported improvement in motor fluctuations. Two studies (Muñoz-Ruiz et al 2020 and Abril-Jaramillo et al 2020) reported changes in the OFF-time in patients with E/S-MF compared to those with advanced PD: mean change 0.8 vs. 1.1 hours and 1.4 vs. 1.5 hours. In one study (Mata el al 2020), patients with E/S-MF showed the greatest benefit. One study (Abril-Jaramillo et al 2020) reported a greater increase in ON-time without disabling dyskinesias in patients with E/S-MF (0.98 vs. 0.82 hours). One study (Bermejo 2020) reported a reduction of the UPDRS-III score of 2.1 points (from 16.2 to 14.1). Abril-Jaramillo et al (2020) reported a reduction of the levodopa dose of 187 mg in patients E/S-MF and 371 mg in patients with advanced PD; Bermejo (2020) reported a dose of levodopa of 395.5 mg at baseline. Two studies (Labandeira et al 2019 and Muñoz Ruiz et al 2020) reported better tolerability results in patients with E/S-MF than in patients with advanced PD including a reduced frequency of disabling dyskinesias and hallucinations. Bermejo (2020) reported that 12.5% of the patients presented adverse events and only one discontinued due to dyskinesia.
Conclusion: Opicapone showed a beneficial profile in terms of improvement of motor fluctuations in patients with E/S-MF and those with advanced PD. However, opicapone was better tolerated in patients with E/S-MF than in those with advanced PD, with a lower rate of hallucinations and disabling dyskinesias. Overall, these results suggest that patients with PD and MF could benefit of an early use of opicapone.
To cite this abstract in AMA style:
M. Mata Alvarez-Santullano, C. Borrue Fernández, CM. Labandeira Guerra, T. Muñoz Ruiz, J. Abril Jamarillo, V. Gómez Mayordomo, PE. Bermejo Velasco. Opicapone in Parkinson’s disease patients with early/simple motor fluctuations: real-world Spanish data [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/opicapone-in-parkinsons-disease-patients-with-early-simple-motor-fluctuations-real-world-spanish-data/. Accessed May 13, 2025.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/opicapone-in-parkinsons-disease-patients-with-early-simple-motor-fluctuations-real-world-spanish-data/